A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

Inclusion Criteria: * Provision of informed consent * Clinically normal physical findings and laboratory values as judged by the investigator including negative test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to hepatitis C virus. Exclusion Criteria: * Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the Investigational Product * History of psychiatric or somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator